Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ANIX logo ANIX
Upturn stock ratingUpturn stock rating
ANIX logo

Anixa Biosciences Inc (ANIX)

Upturn stock ratingUpturn stock rating
$3.3
Last Close (24-hour delay)
Profit since last BUY-2.94%
upturn advisory
Consider higher Upturn Star rating
BUY since 15 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ANIX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $9

1 Year Target Price $9

Analysts Price Target For last 52 week
$9Target price
Low$2.07
Current$3.3
high$4.2

Analysis of Past Performance

Type Stock
Historic Profit -57.93%
Avg. Invested days 26
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 106.30M USD
Price to earnings Ratio -
1Y Target Price 9
Price to earnings Ratio -
1Y Target Price 9
Volume (30-day avg) 3
Beta 0.33
52 Weeks Range 2.07 - 4.20
Updated Date 06/30/2025
52 Weeks Range 2.07 - 4.20
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.39

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Revenue by Geography

Earnings Date

Report Date 2025-06-06
When -
Estimate -0.1
Actual -0.09

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -39.75%
Return on Equity (TTM) -65.38%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 90276381
Price to Sales(TTM) 481.54
Enterprise Value 90276381
Price to Sales(TTM) 481.54
Enterprise Value to Revenue 368.98
Enterprise Value to EBITDA -8.76
Shares Outstanding 32211100
Shares Floating 30497784
Shares Outstanding 32211100
Shares Floating 30497784
Percent Insiders 5.32
Percent Institutions 17.6

Analyst Ratings

Rating 2
Target Price 9
Buy 2
Strong Buy 1
Buy 2
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Anixa Biosciences Inc

stock logo

Company Overview

overview logo History and Background

Anixa Biosciences, Inc. is a biotechnology company focused on developing therapies and vaccines that address critical unmet needs in oncology and infectious diseases. Founded in 2011, it has evolved from an early-stage company to one with several clinical-stage programs.

business area logo Core Business Areas

  • Cancer Immunotherapy: Developing therapies that use the body's immune system to fight cancer. This includes a novel CAR-T therapy approach and a cancer vaccine technology.
  • Infectious Disease Therapeutics: Focused on developing therapeutics for infectious diseases, including a potential treatment for COVID-19.

leadership logo Leadership and Structure

The leadership team consists of individuals with experience in biotechnology, pharmaceuticals, and finance. The organizational structure is typical of a small biotech company, with research, development, and management functions.

Top Products and Market Share

overview logo Key Offerings

  • CAR-T Therapy: Developing a novel CAR-T therapy that targets solid tumors. While not yet approved, if successful, it could address a significant unmet need in the treatment of solid tumors. Competitors include major pharmaceutical companies that are developing CAR-T therapies for hematological malignancies, such as Novartis and Gilead.
  • Cancer Vaccine: Developing a vaccine to prevent certain cancers, initially focusing on triple-negative breast cancer. This program is in preclinical stages. The market share is currently 0%. Competitors include companies focused on cancer vaccines, such as Moderna and BioNTech.

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is characterized by high levels of innovation, intense competition, and regulatory scrutiny. There is growing demand for novel therapies, especially in oncology and infectious diseases.

Positioning

Anixa Biosciences is positioned as an innovative biotech company focused on developing novel therapies and vaccines. Its competitive advantage lies in its proprietary technologies and its focus on unmet medical needs.

Total Addressable Market (TAM)

The TAM for cancer immunotherapy and vaccines is estimated to be worth billions of dollars annually. Anixa's positioning aligns with capturing a segment of this large TAM through innovative solutions.

Upturn SWOT Analysis

Strengths

  • Proprietary Technologies
  • Focus on Unmet Medical Needs
  • Experienced Management Team
  • Pipeline of Clinical-Stage Programs

Weaknesses

  • Limited Financial Resources
  • Dependence on Clinical Trial Success
  • Competition from Larger Companies
  • Lack of Approved Products

Opportunities

  • Positive Clinical Trial Results
  • Partnerships with Larger Pharmaceutical Companies
  • Expansion into New Therapeutic Areas
  • Government Funding and Grants

Threats

  • Clinical Trial Failures
  • Regulatory Hurdles
  • Competition from New Therapies
  • Economic Downturn

Competitors and Market Share

competitor logo Key Competitors

  • MRNA
  • BNTX
  • NVS
  • GILD

Competitive Landscape

Anixa faces stiff competition from larger, more established pharmaceutical and biotechnology companies. Its advantages include its innovative technologies and focus on unmet medical needs. Its disadvantages include limited financial resources and lack of approved products.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by expansion of the pipeline and advancement of programs into clinical trials.

Future Projections: Future growth is dependent on positive clinical trial results and potential partnerships.

Recent Initiatives: Recent initiatives include advancing the CAR-T program and cancer vaccine into clinical development.

Summary

Anixa Biosciences is a development-stage biotechnology company with promising technology but limited resources. Its success is dependent on positive clinical trial results and the ability to secure partnerships or funding. Investors should be aware of the high level of risk associated with investing in development-stage biotech companies, but the potential returns could be substantial if Anixa's therapies are successful. They should look out for competition from big pharma and any negative regulatory changes.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (SEC)
  • Analyst Reports
  • Company Press Releases
  • Yahoo Finance

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Anixa Biosciences Inc

Exchange NASDAQ
Headquaters San Jose, CA, United States
IPO Launch date 1987-01-01
CEO, Chairman & Co-Chair of CBAB Dr. Amit Kumar Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 5
Full time employees 5

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.